Rapport Therapeutics Inc (RAPP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2023 | 06-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||
| Net Income | -21,267 | -12,558 | -10,652 |
| Depreciation Amortization | 59 | 36 | 15 |
| Accounts payable and accrued liabilities | 131 | -502 | N/A |
| Other Working Capital | 708 | -1,576 | 1,488 |
| Other Operating Activity | 3,545 | 3,200 | 5,907 |
| Operating Cash Flow | $-16,824 | $-11,400 | $-3,242 |
| Cash Flows From Investing Activities | |||
| PPE Investments | -199 | -147 | -284 |
| Other Investing Activity | 0 | 0 | -5,000 |
| Investing Cash Flow | $-199 | $-147 | $-5,284 |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 54 | 54 | N/A |
| Common Stock Repurchased | -4 | N/A | N/A |
| Other Financing Activity | 145,226 | 59,862 | 39,685 |
| Financing Cash Flow | $145,276 | $59,916 | $39,685 |
| Beginning Cash Position | 31,159 | 31,159 | 0 |
| End Cash Position | 159,412 | 79,528 | 31,159 |
| Net Cash Flow | $128,253 | $48,369 | $31,159 |
| Free Cash Flow | |||
| Operating Cash Flow | -16,824 | -11,400 | -3,242 |
| Capital Expenditure | -199 | -147 | N/A |
| Free Cash Flow | -17,023 | -11,547 | -3,242 |